1.. Introduction
================

The oligomerization and then fibrillation of misfolded proteins is a common feature of a large group of diseases referred to as protein misfolding diseases (PMDs). A subset of these diseases is known as neurodegenerative because they cause irreversible damage to the central nervous system (CNS). Several different proteins may precipitate the clinical symptoms of these conditions, several parts of the CNS may be damaged and the mechanism of the condition varies ([Table 1](#TN_1){ref-type="table"}). The best known examples of neurodegenerative PMDs include Parkinson's \[[@B1],[@B2]\] and Alzheimer's \[[@B2]-[@B4]\] diseases (PD and AD, respectively). Prionic diseases are less common and less predictable than the others but their immediate clinical impact can be more dramatic \[[@B5],[@B6]\]. There are also a number of hereditary conditions also counted among the neurodegenerative PMDs, the most well- known of these being Huntington's Disease (HD) \[[@B7]\]. While the exact nature and relevance of protein misfolding is sometimes debated, for instance the relevance and nature of Huntingtin (Htt) aggregation in HD \[[@B8],[@B9]\], there is agreement that misfolded, mis-aggregated or wrongly processed proteins are the unifying feature of these conditions \[[@B10]\]. Full recovery has not yet been observed in any patient after damage to nerve tissue has begun. Clear and early diagnosis of these conditions is therefore essential for informing sufferers about their condition, managing the condition where this is possible and giving appropriate palliative care. Theoretically, early diagnosis might help guide choice of treatment in cases where effective options are available.

###### Neurodegenerative protein misfolding diseases

  ----------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protein Misfolding Disease                                                                            Aggregating protein(s)                                           Aetiology                                                                Clinical Manifestation                                                                                                                                                                                                                                                                        Pathogenic mechanism
  AD                                                                                                    Aβ, Tau \[[@B128]\]                                              Acquired; age, gene variants increase risk, see also familial forms      Dementia, language difficulties, executive dysfunction, depression, hallucinations, delusions, agitation, apathy, disinhibition \[[@B128]\]                                                                                                                                                   Depositions of Aβ plaques and Tau tangles observed. Selective loss of cholinergic neurones, loss of synapses and neurones in the cerebral cortex, atrophy of frontal cortex cingulate gyrus, temporal lobe and parietal lobe \[[@B129]\]
  Cerebral amyloid angiopathy                                                                           Aβ, BRI2, Cystatin C, gelsolin, PrPSc, Transthyrin \[[@B130]\]   Acquired; age, familial factors and familial subtypes types identified   Cerebral haemorrhage, ischemic lesions, progressive dementia \[[@B130]\]                                                                                                                                                                                                                      Progressive deposition of amyloid protein in cerebral blood vessel walls leading to degenerative vascular changes \[[@B130]\]
  PD                                                                                                    α-Syn, Tau \[[@B131],[@B132]\]                                   Acquired; head trauma, specific gene variants known to increase risk     REM sleep behaviour disorder, Excessive daytime sleepiness, hyposmia, depression, bradykinesia, rigidity, tremors, mild cognitive impairment, dyskinesia, dysphagia, postural instability, freezing of gait, orthostatic hypotension \[[@B131]\]                                              Manifestation of Lewy bodies enriched in α-Syn. Loss of dopaminergic neurons in the substantia nigra, Neuroinflammation with reactive gliosis and microgliosis \[[@B131]\]
  Frontotemporal lobar degeneration                                                                     Tau, TDP-43, FUS, p62, ubiquitin \[[@B133]\]                     Major genetic contributions \[[@B134]\]                                  Personality changes, behavioural disinhibition, apathy, progressive aphasia \[[@B53]\]                                                                                                                                                                                                        Neuronal loss, gliosis, microvacular changes of frontal lobes, anterior temporal lobes, anterior cingulate cortex and insular cortex \[[@B133]\]
  Huntington's disease                                                                                  Htt \[[@B135]\]                                                  Congenital, monogenic                                                    Mild psychotic and behavioural symptoms, progressive chorea, rigidity, dementia, dystonia, bradykinesia \[[@B135]\]                                                                                                                                                                           Gross striatal atrophy, neuronal loss in neocortex, cerebellum, hippocampus, substantia nigra, and brainstem nuclei \[[@B135]\]
  Familial British dementia, and Familial Danish dementia                                               BRI2 \[[@B136]\]                                                 Congenital, monogenic                                                    Progressive cognitive impairment, spastic tetraparesis, cerebellar ataxa \[[@B137]\]                                                                                                                                                                                                          Amyloid angiopathy and neurofibrillary tangles (NFTs) in the hippocampus \[[@B136]\]
  CADASIL, Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy   NOTCH3 \[[@B138]\]                                               Congenital, monogenic \[[@B139]\]                                        Mood disturbances, apathy, subcortical ischemic events, migraine with aura, cognitive impairment \[[@B138]\]                                                                                                                                                                                  Degeneration of smooth muscle cells in blood vessels \[[@B138]\]
  Alexander disease                                                                                     GFAP \[[@B140]\]                                                 Sporadic; gene variants increase risk                                    Macrocephaly, frontal leukodystrophy, palatal tremors, dysphagia, cognitive delays, seizures \[[@B140]\]                                                                                                                                                                                      Demyelination, Rosenthal fibres in astrocytes \[[@B141]\]
  Familial encephalopathy with neuroserpin inclusion bodies                                             Neuroserpin \[[@B142]\]                                          Congenital, monogenic \[[@B143]\]                                        Dementia, epileptic, seizures, progressive myoclonus, dysarthria \[[@B142]\]                                                                                                                                                                                                                  Poorly understood, encephalopathy with neuroserpin inclusion bodies \[[@B142]\]
  Kuru                                                                                                  PrP \[[@B144]\]                                                  Acquired; transmitted                                                    Cerebellar ataxia, choreifrom, athetoid movements, nystagmus, dysphasia \[[@B144]\]                                                                                                                                                                                                           Spongiform change, neuronal loss, astrocytic microgliosis, kuru plaques \[[@B144]\]
  Creutzfeldt-Jakob disease                                                                             PrP \[[@B145]\]                                                  Acquired; transmitted                                                    Dementia, myoclonus, visual or cerebellar disturbance, akinetic mutism, pyramidal or extrapyramidal signs \[[@B146]\]                                                                                                                                                                         Spongiform change, neuronal loss, gliosis \[[@B145]\]
  Gerstmann-Straussler-Scheinker syndrome                                                               PrP \[[@B144]\]                                                  Major genetic contributions \[[@B147]\]                                  Cerebellar ataxia, gait abnormalities, dementia, dysarthria, ocular dysmetria, myoclonus, spastic paraparesis, parkinsonism, hyporeflexia or areflexia in lower extremities \[[@B144]\]                                                                                                       Amyloid plaques, severe to absent spongiform changes, neuronal loss, astrocyte microgliosis, variable neurofibrillary tangles \[[@B144]\]
  Fatal familial insomnia                                                                               PrP \[[@B144]\]                                                  Congenital, monogenic \[[@B148]\]                                        Insomnia, myoclonus, ataxia, dysarthria, dysphagia, pyramidal signs, autonomic hyperactivation \[[@B144]\]                                                                                                                                                                                    Neuronal loss, astrogliosis, hypometabolism in the thalamus and cingulate cortex \[[@B144]\]
  Progressive supranuclear palsy                                                                        Tau \[[@B149]\]                                                  Acquired; head trauma \[[@B150]\]                                        Progressive axial rigidity, vertical gaze palsy, dysarthria, dysphagia \[[@B149]\]                                                                                                                                                                                                            Neuronal loss, gliosis, neurofibrillary tangles affecting brainstem, basal ganglia, diencephalon \[[@B149]\]
  Chronic traumatic encephalopathy                                                                      Tau, TDP-43 \[[@B151]\]                                          Acquired; head trauma \[[@B152]\]                                        Learning and memory impairment, anterograde amnesia, executive dysfunction, depression, apathy, irritability, suicidality, loss of impulse control, dementia, PD, dysarthria \[[@B151]\]                                                                                                      Atrophy of frontal and temporal cortices and medial temporal lobe, atrophy of the thalamus, hypothalamus and mammillary bodies. Thinning of the corpus callosum, pallor of the substantia nigra and locus coeruleus, cavum septum pellucidum \[[@B151]\]
  Lytico-Bodig disease                                                                                  Tau \[[@B153]\]                                                  Acquired                                                                 Global dementia, progressive aphasia, gaze palsy, parkinsonism, progressive supranuclear palsy \[[@B153]\]                                                                                                                                                                                    Poorly understood, neurofibrillary tangles are found in the brain \[[@B153]\]
  Meningioangiomatosis                                                                                  Tau \[[@B154]\]                                                  Acquired                                                                 Epileptic seizures, haemorrhagic stroke, anginoma, status epilepticus, generalized tonic--clonic seizures \[[@B155]\]                                                                                                                                                                         Focal lesion of the leptomeninges and underlying cerebral cortex \[[@B155]\]
  Neuronal Ceroid Lipofuscinosis                                                                        ATP synthase subunit c, saposin A, saposin D \[[@B156]\]         Congenital, monogenic, subtypes exists \[[@B157]\]                       Hypotonia, myoclonic jerks, generalized epileptic seizures, developmental regression, optic atrophy, macular degeneration, spastic tetraplegia, blindness, severe and constant microcephaly, and pharmaco-resistant epileptic seizures, myoclonia, ataxia, extrapyramidal signs \[[@B156]\]   Cerebellar and cortical atrophy, loss of pyramidal neurons and Purkinje cells, reactive astrogliosis \[[@B156]\]
  Argyrophilic grain disease                                                                            Tau \[[@B158]\]                                                  Acquired; old age \[[@B158]\]                                            Cognitive decline, dementia, mood imbalance, personality changes, behavioural abnormalities \[[@B158]\]                                                                                                                                                                                       Argyrophilic grains in trans entorhinal cortex, entorhinal cortex, hippocampus, presubiculum, temporal cortex, orbitofrontal cortex, insular cortex, and amygdala\[[@B158]\]
  ----------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The desire for both prompt diagnosis and improved medical treatments has thus encouraged research into misfolded protein aggregates and their relative PMDs. Diligent research has identified and characterised many of the individual proteins involved in these conditions. For example, β-amyloid (Aβ) \[[@B11]\] and Tau in AD \[[@B12]\], *α*-Synuclein ( *α*-Syn) in PD \[[@B13],[@B14]\] and Htt in HD \[[@B7]\] are now largely accepted to have key roles in these diseases (For other protein involvement in given diseases, see [Table 1](#TN_1){ref-type="table"}). Despite this, tests for diagnostic compounds (biomarkers) are not in routine use for identifying any of the non-hereditary PMDs. For instance, when assessing patients for AD, clinicians have to rely on an imaging or visual data regarding symptoms and standardized tests that are sometimes combined with MRI \[[@B7]\]. Biopsies for detecting changes in the CNS are considered invasive procedures that are generally unsuitable for elderly patients, and thus they are usually only used for verification of the diagnosis post mortem \[[@B15]\]. Importantly, tissue damage precedes the formation of the characteristic insoluble fibrils that are detected in brains of AD sufferers. Such fibrils are not cytotoxic and their formation correlates only poorly with disease progression \[[@B16]\]. This suggests that other agents, such as oligomers of the same misfolded proteins as the fibrils, are responsible.

The common features of neurodegenerative PMDs, in which only one or two proteins appear to be defective, or at least the processing of which is defective, is an attractive target for translational research aiming to detect the condition in its early stages. One possible diagnostic tool is therefore a detection system for the activity of proteases that are also involved in the progression of the disease, such as caspase-8 activation in the case of PD \[[@B17]\] and β- and γ-secretase in AD \[[@B18],[@B19]\]. One problem with this approach is that such processes do not have a unique association with the diseases in question. Another approach would be to focus on the individual misfolded proteins at an early stage, rather than the insoluble plaques and reduction in tissue volume associated with advanced stages. Sensitive tools are required for the early detection of conditions where the underlying biochemical changes may be small or difficult to resolve. For example, only minute quantities of transmissible misfolded prions are required to precipitate Creutzfeldt-Jakob Disease (CJD) in humans \[[@B6]\], bovine spongiform encephalopathy (BSE) and scrapie in sheep \[[@B20]\]. Nor is it necessarily straightforward to detect changes in protein folding, aggregation or processing in bodily fluids. Despite these challenges, methods for monitoring such changes in the relevant proteins of PMDs are of clinical interest. In this review, we explore recent advances in translational research focused on detecting misfolded proteins in the context of early pre-fibril misfolding. We discuss these advances from both a research and a clinical perspective. We conclude with a forward-looking view on possible research directions.

2.. Protein misfolding, oligomerisation and toxicity
====================================================

Proteins pass through a fundamental process called folding in order to obtain their functional structure \[[@B21]-[@B23]\]. Folding is usually spontaneous under physiological conditions, and occurs at rates that depend upon the protein's size \[[@B24]\]. This process takes a couple of hundred milliseconds for most proteins \[[@B25]\]. Early steps in protein folding include the clustering of hydrophobic amino acids and the expulsion of water, the subsequent compaction of the polypeptide chain and consolidation of secondary structure. Then, a re-ordering and fine-tuning of the structural elements takes place to afford the final tertiary structure. The folding process needs to make particular intra-fold contacts both in its early and late stages. All these steps are affected by the protein's environment. Factors that affect the outcome of a folding process and aggregation behaviour include solvent conditions, the presence or absence of cofactors and metal cations \[[@B26]\], chaperones or other dissolved factors, crowding from other proteins or macromolecular aggregates, spatial organization and post-translational modification (reviews \[[@B27],[@B28]\]). The fact that folding is influenced by many factors is also reflected in the cell biology of the PMDs. The state of the prion protein associated with CJD is both translocated into the ER and glycosylated differently than its non-pathogenic counterparts \[[@B29],[@B30]\]. Copper and zinc ions are implicated in both AD and PD, as there is evidence that they influence disease onset and progress in animal models and have been highlighted in clinical studies \[[@B31]\]. It is not entirely clear whether Cu^2+^ and Zn^2+^ are only involved in the misfolding of proteins or also in the aggregation of those proteins into fibrils \[[@B32]\].

Amyloid fibrils are widely recognized as a result of protein misfolding and have been observed both *in vitro* and *in vivo*. They are repetitive sheets in which monomers are joined by hydrogen bonds across β-strands. The long sheets are slightly twisted, with varying dimensions and crossover distances depending on the polypeptide involved. Cryo-electron microscopy has indicated that in Aβ the fibril is approximately 4 nm and 11 nm at the narrowest and widest points respectively and has a twist crossover distance that has a mean of about 100 nm. Comparative work on fibril morphology from A *β* and *α*-Syn indicates that they are similar, but with a degree of polymorphism \[[@B33]-[@B35]\]. A considerable range of proteins and protein fragments can form fibrils, suggesting that the barrier to formation of these states is more likely to rest with time and physico-chemical conditions than amino acid sequence.

Importantly, the extent of fibril formation does not appear to correlate with disease progression and naturally occurring mutants associated with the early onset of PMDs do not produce more fibrils \[[@B16]\]. For these reasons, attention has been given to the aggregates preceding fibril formation. It has been proposed recently that the toxic oligomers are, just like fibrils, a general phenomenon that forms relatively independently of protein sequence \[[@B36]\]. The oligomerisation of other proteins such as calcitonin \[[@B37]\], *α*-Syn \[[@B38]\], Syrian hamster prion protein \[[@B39]\], GAP-43 and BASP1 \[[@B40]\] is consistent with this. The oligomers have since been shown to display significant toxicity-related effects relative both to monomers, fibrils and proto-fibrils \[[@B41],[@B42]\]. Furthermore, rates of their formation are better able to account for disease-promoting mutations \[[@B16],[@B37],[@B42],[@B43]\]. It has also been suggested that their toxicity is linked to membrane damage through a pore-like action \[[@B44]\] and a range of pre-fibrillar oligomeric structures from a several proteins, including Aβ, Htt, prion proteins, and *α*-Syn, has since been investigated in this context \[[@B39],[@B43],[@B45],[@B46]\].

3.. Misfolded proteins and the lipid profile of the membrane
============================================================

It is well established that membrane or peripheral proteins may affect membranes and *vice versa* (review \[[@B47]\]). The lipid-dependent, differential processing of APP to A *β* is one particularly relevant example of this \[[@B48]\]. Moreover, PMD proteins and notably their oligomeric states have considerable effects on membrane integrity. Furthermore, tissue deposits of amyloid fibrils contain lipids \[[@B49]\]. Imaging studies on prefibrillar oligomers reveal a range of structures, some of which may have a pore-like morphology (review \[[@B50]\]). These are referred to as amyloid pores or sometimes annular oligomers \[[@B51]\]. Whether such oligomers will go on to form mature amyloid fibrils exclusively is not clear, as there exists reports in which pore-like oligomers do not appear to undergo fibrillation \[[@B52]\]. Certain drugs can arrest fibril but not oligomer formation \[[@B53]\]. Even though the presence of non-fibrillar, pore-like oligomers correlates better with toxicity and disease-promoting mutants than fibrils, their properties, mechanism of action and what promotes or suppresses their formation remains poorly understood.

Two competing hypotheses that may explain the effect of oligomers on the membrane are being researched at the moment. The first suggests that oligomer toxicity is a direct result of pore formation. Examples of oligomers that may effect pore formation include those generated by islet amyloid polypeptide \[[@B54]-[@B57]\], poly-glutamine \[[@B58]\], transthyretin \[[@B59]\], prion protein fragment \[[@B60]\], A*β* \[[@B61]\], *β*2-microglobulin \[[@B62]\] and serum amyloid A \[[@B63]\]. Porosity was indicated by ionic flux across reconstituted membranes, which compromises cellular homeostasis and membrane potential \[[@B61]\]. The second hypothesis being tested at present is that the oligomers cause membrane thinning rather than leakage, through a distinct pore \[[@B42],[@B64],[@B65]\]. In this scenario, leakage through the membrane is independent of the pore-like aggregate morphologies and can take place through any area of the membrane that is sufficiently perturbed by these aggregates. Membrane thinning involves the increase of area per lipid and intercalation of polypeptides and water molecules between head groups in order to avoid energetically costly vacuums in the lateral lipid packing. This has the effect of lowering the dielectric barrier and allowing ion leakage through the membrane \[[@B10],[@B66]\].

Experimental determination of leakage through a pore formation or through thinning of the membrane is not straightforward. Regardless of the particular mechanism, the oligomers convey toxicity by perturbing the integrity of the membrane. However, the membranes may in turn affect the oligomers, too. Aggregating, oligomeric peptides have been shown to have preferential binding to particular membrane components, in particular sphingolipids and cholesterol. Sphingolipids and cholesterol are found in patches termed the liquid ordered phase that are often referred to as lipid rafts \[[@B67]\], though controversy about this link exists \[[@B68]\]. Glycosphingolipids and gangliosides have affinity for the Aβ peptide in AD and *α*-Syn interacts with GM~1~ and GM~3~ gangliosides \[[@B69]-[@B74]\]. PrP has been associated with sphingolipid signalling platforms and bind to sphingomyelin, GalCer, GM~1~ and GM~2~ \[[@B70],[@B75],[@B76]\]. A strong interaction with sphingolipids may reflect the amount of amyloidogenic protein found in possible lipid raft areas of the extracellular leaflet of the plasma membrane \[[@B49]\]. Amyloidogenic proteins such as *α*-Syn also interact more strongly with anionic lipids phosphatidylglycerol and phosphatidylserine, found mainly in the cytoplasmic leaf \[[@B45],[@B77]-[@B79]\]. Model systems comprising the anionic lipids cardiolipin, phosphatidic acid or phosphatidylglycerol leak more on contact with oligomers \[[@B45]\].

The role of cholesterol in membrane behaviour has been researched in some depth \[[@B80]-[@B88]\] but its role in oligomer formation and amyloidogenesis remains disputed and controversial \[[@B89]\]. Cholesterol has been shown to bind to Aβ proto-fibrils, but how these interactions influence oligomerization and later fibrillogenesis remains unclear \[[@B90]-[@B92]\]. There is evidence that cholesterol can have a stabilizing effect on membrane permeability as it reduces the leakage induced by *α*-Syn \[[@B46]\]. The role of cholesterol in the proteolysis of APP to give A *β* is better understood. Proteolysis of APP is inhibited by the group of cholesterol synthesis inhibitors known as statins \[[@B93],[@B94]\]. In PD a depletion of cholesterol leads to a decreased level of *α*-Syn in membrane fractions in neuronal cell cultures and mouse brains \[[@B95]\]. Inhibition of cholesterol synthesis also reduces the levels of *α*-Syn in membranes, but the opposite applies to cholesterol supplementation in neuronal cells \[[@B96]\]. It has also been suggested that oxidised cholesterol accelerates aggregation of *α*-Syn \[[@B97]\].

This evidence may be at odds with the observation that cholesterol protects artificial membranes against oligomerinduced leakage \[[@B46]\] as it fails to provide a direct connection to the proposed toxicity mechanism. Polyunsaturated fatty acids may have an inhibitory role in oligomerization. The presence of docosahexaenoic acid (DHA) suppresses the toxicity of A *β* towards SH-SY5Y cells by interfering with its aggregation \[[@B98],[@B99]\], and appears to have a neuro-protective role in murine models for AD \[[@B100]\]. However, DHA can also affect the progress of some cells through the cell cycle \[[@B101]\]. The notion that saturation levels of the fatty acid residues (FARs) of phospholipids in membranes play a role in modulating the rate of oligomerization agrees with measurements from model systems that indicate that saturated fatty acid residues lower the energetic barrier to aggregation \[[@B102]\].

Further work is required to understand the complexities of the relationship between membrane components and protein misfolding and oligomerization. It is possible that certain lipids or other membrane components may be used as diagnostic compounds for more reliable early-stage detection of neurodegenerative PMDs in combination with detection of the oligomeric proteins, should the links between lipid species and oligomerization prove robust.

4.. Clinical detection of protein aggregates
============================================

There is no single rigorous assay for diagnosis of any PMD. The mounting evidence for the involvement of toxic oligomers in neurodegeneration confers an increasing importance on detection methods for basic and translational research, and in clinical practice. As a result, great research effort is being focused on developing clinical methods for detecting the main pathological unit of AD. At present, diagnosing AD includes a test of cognitive impairment (The Mini Mental State Exam or Folstein test), in some cases supplemented by CSF assays for phosphorylated tau and A*β*, MRI for brain volume and PET scans for Aβ plaques (or glucose metabolism) in the brain \[[@B103]\].

An overview of methods for clinical detection of protein aggregates is shown in [Table 2](#TN_2){ref-type="table"}. Generally, approaches for the identification of protein aggregates can be divided into three classes of method: (i) visualization of protein aggregates in biopsies, (ii) monitoring of marker peptide in bodily fluids, and (iii) visualization of protein aggregates *in vivo* using imaging techniques. Most of the methods discussed here concern Aβ peptide detection in AD, as this field has advanced the furthest. The majority of approaches rely on antibodies to confer specificity to the detection, whether it occurs in biopsies, bio-fluids or *in vivo*. A considerable number of different antibodies have been developed in the last two decades, many of which have at least some degree of specificity towards the proteins and aggregation-states involved in neurodegenerative PMDs. An overview of some of their properties is shown in [Table 3a](#TN_3a){ref-type="table"}.

The visualization of amyloid plaques in samples from biopsies is a well-established means for qualitative detection of mature fibrils. There are several standard stains, such as Congo red and fluorescent thioflavins \[[@B104]\], as well as immunohistology stains based on antibodies \[[@B105]\]. There have been several recent advances in the development of fluorescent probes based on luminescent conjugated oligothiophenes (LCOs) which can be used for investigating the nature of these protein deposits \[[@B106],[@B107]\]. LCOs are able to illuminate more protein deposit plaques than other fluorophores \[[@B108]\]. Moreover, the emission spectra of LCOs are dependent on the type of predominant peptide present. This makes it possible to distinguish e.g. AD-associated aggregates from other types of aggregates \[[@B109],[@B110]\]. Another new and promising way of detecting of amyloid plaques is the discovery of photo-induced electron transfer probes that can be used to detect Aβ aggregates without the need of a washing step \[[@B111]\]. These recently-developed fluorescent probes represent a new opportunity in direct and sensitive identification of protein aggregates, especially in complex biological environments.

The second class of methods for the detection of proteins and their aggregates detects molecules in bio-fluid samples, avoiding the need for biopsies. These clinical methods rely on the detection of marker peptides in cerebrospinal fluid (CSF). For instance, detection of A *β* or tau protein in AD has been shown to have predictive power over which individuals will go on to develop the disease \[[@B112]\]. Detection of the relevant molecular species in CSF is relatively straightforward and a broad array of methods exists for its detection. It is possible to detect and quantify tau peptides in the lower ng/mL range using mass spectrometry on samples acquired directly from the CNS \[[@B12]\], although this not in routine clinical use yet.

A more common method is the use of enzyme-linked immuno-sorbent assays (ELISA) \[[@B113]\]. For example, antibodies 2G3 and 21F12 are used for the detection of C-terminal amino acids of A*β* peptides 1-40 and 1-42, respectively, in diagnosis of AD \[[@B114]\]. The same peptides can be detected by new electrochemical detection immuno-sensors. These biosensors are based on immobilization of antibodies on gold nanostructured screen-printed electrodes with cyclic voltammetry detection \[[@B115]\], or with difference pulse voltammetry detection with immobilization on gelsolin coated electrodes that selectively binds A*β* peptides \[[@B116]\]. Another interesting approach combines ELISA and surface plasmon resonance to provide greatly enhanced detection, using gold nano-particles conjugated with antibodies \[[@B117]\]. The role of the nano-particles in this assay is to increase the change in refractive index response that each immobilized molecule produces. This provides detection limits as low as single molecules. This technique is also designed to handle precipitates as part of the detection assay, which may be an advantage when working with oligomerization states. The last group of methods allow direct observation of amyloid plaques in vivo. This direct observation is appealing for clinical use, but is not yet practiced routinely. Methods like magnetic resonance imaging (MRI), positron emission tomography (PET) \[[@B118]\] and diffusion-tensor imaging \[[@B119],[@B120]\] are being developed for direct diagnosis of amyloid plaques based on visual inspection of advanced imaging output. However, all of these methods are based only on qualitative approaches and rely on detecting visible changes in the CNS. There has been some work on quantification of amyloid loads based on PET image analysis but with very limited results \[[@B118],[@B121]\]. More recent advances in MRI are based mainly on the use of particles that allow localization of particular plaques. For example it is possible to use curcumin-conjugated magnetic nano-particles \[[@B122]\] or hollow manganese oxide nano-particles conjugated with a particular antibody \[[@B123]\]. Both of these nano-particle methods increase the specificity and sensitivity of the techniques towards the protein aggregates. However, these approaches are not in routine use and may not satisfy the need for diagnosis before irreparable damage to tissue has occurred.

###### Clinical detection of protein aggregates

  -------------------------------------------------------------------------------------------------- ---------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Proteopathy                                                                                        Misfolding/oligomerizing protein   Current methods for clinical detection

  AD                                                                                                 Aβ peptide                         Decrease of marker peptide concentration in CSF, detected by ELISA, immuno-sensors \[[@B112],[@B113],[@B115]\]\
                                                                                                                                        \
                                                                                                                                        MRI with plaque selective magnetic nanoparticles -- hollow manganese oxide nanoparticles coated with antibody or curcumin-conjugated magnetic nanoparticles \[[@B123]\]\
                                                                                                                                        \
                                                                                                                                        Fluorescent labelling of biotic samples with luminescent conjugated oligothiophenes \[[@B106],[@B107],[@B109]-[@B111]\]\
                                                                                                                                        \
                                                                                                                                        Late phase PET imaging of cerebral fibrillary Aβ peptide with 11C-Pittsburgh compound B as a PET ligand \[[@B159],[@B160]\]

                                                                                                     Tau protein                        Ratio of phosphorylated Tau in position 396 and 404 in CSF could discriminate AD from other dementia; Identification by ELISA \[[@B161]\]\
                                                                                                                                        \
                                                                                                                                        Identification of phosphorylated biomarkers pTau181, pTau199 and pTau231 in CSF by immunoassays \[[@B162]-[@B167]\]

  Cerebral amyloid angiopathy                                                                        Aβ peptide                         Early phase PET imaging of cerebral fibrillary β-amyloid with 11C-Pittsburgh compound B as a PET ligand \[[@B168]-[@B170]\]

  PD                                                                                                 α-Syn                              Detection of α-Syn aggregates in biotic samples by imunohistochemical or fluorescent staining \[[@B171]-[@B173]\]\
                                                                                                                                        \
                                                                                                                                        Multi-parametric fluorescent pyrene-labelling of biotic samples \[[@B174]\]\
                                                                                                                                        \
                                                                                                                                        Detection of α-Syn oligomers in human plasma or red cells by ELISA \[[@B175],[@B176]\]

  Huntington's Disease                                                                               Htt                                Loss of brain volume observed by MRI with combination of genetic test -- identification of abnormal CAG expansion in exon1 of htt gene \[[@B177]-[@B179]\]

  Variant Creutzfeldt-Jakob disease                                                                  Prion protein PrP                  Whole blood immunoassay \[[@B180]-[@B182]\]

  Other prion diseases:                                                                              Prion protein PrP                  Conformation dependent immunoassays in biopsy samples\[[@B183],[@B184]\]

  Gerstmann-Sträussler-Scheinker disease, fatal familial insomnia, kuru, Creutzfeldt-Jakob Disease                                      

                                                                                                                                        Analysis of 14-3-3 and PrPSc expression pattern in CSF \[[@B185]\]

                                                                                                                                        Detection of PrPSc in urine by immunoassay \[[@B186],[@B187]\]
  -------------------------------------------------------------------------------------------------- ---------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

5.. Concluding remarks and future perspectives
==============================================

The methods available for detecting proteins associated with neurodegenerative PMDs shows some promise for clinical use. However, many of these methods make no distinction between monomers or oligomers. Thus, the preparation of diagnostic tools that monitor the advancement of oligomerization at an early stage is still under development.

Antibodies are one of the most well established and still promising directions for developing diagnostic tools. Antibodies with ligand conformation sensitivity could be used to build one or more specific standardized clinical ELISA assays for detection of misfolded oligomers. The reliability of such immuno-based approaches is limited by the quality of the antibody involved. Notably, antibody-based detection of the misfolded oligomers, for instance Tau and A *β*, has advanced in recent years (see [Table 3a](#TN_3a){ref-type="table"}), indicating that standard assays based on immunology may indeed be made sensitive to oligomeric forms. Ensuring that there is a low limit of detection in a complex bio-fluid is also a concern, for ensuring early diagnosis.

Another approach could be the use of native mass spectrometry for detecting protein aggregates. It is a technique which, in contrast to other types of mass spectrometry, can detect non-covalent interactions between proteins \[[@B124]\]. This technique is also able to detect protein complexes across a wide range of molecular masses and handles heterogeneous samples well. All these features are attractive when aiming to detect oligomers in complicated samples such as bio-fluids. Native mass spectrometry has been used successfully to investigate the assembly of virus capsid, directly from crudely purified culture extract \[[@B125]\]. In principle, it is also possible to detect the oligomers discussed above. An overview of recent, promising use of mass spectroscopy in neurodegenerative PMDs can be found in [Table 3c](#TN_3c){ref-type="table"}.

The detection of protein glycosylation may be a means for detecting prionic diseases at an early stage (See [Table 3b](#TN_3b){ref-type="table"} for references). This approach relies upon detailed knowledge of the glycosylation chemistry involved. Although mass spectrometry may be helpful in identifying prion protein glycosylation species, the most promising tool at present are lectins. These are saccharide-binding proteins that can detect differences in glycosylation with some specificity and made a distinction between normal and disease-associated prionic protein successfully \[[@B126]\]. One limit to this approach is the ubiquity of glycosylation; it may not be clear which protein the sugars are actually attached to. For these reasons, false positive results may be a significant problem unless the detection method can also identify the protein involved clearly. Fortunately, many well-stablished antibodies may help solve this problem ([Table 3a](#TN_3a){ref-type="table"}), although extensive glycosylation may sometimes obscure the epitopes involved.

###### Oligomeric protein states detected by antibodies

  ------------------------------ ---------- --------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------
  Aggregating protein            Antibody   Specificity and epitope                                                                 Cross-reactions                                                                                                          Detection Methods and References
  Aβ-peptide                     4G8        Recognizes residue 18-23 in Aβ sequence, in its fibrils and fibrillary oligomers form   α-Syn, IAPP, Tau These cross-reactions are reported to be fibril-associated, not sequence dependent                      WB, IHC, IP, ELISA \[[@B188]-[@B190]\]
                                 A11        Prefibrillar oligomers, not monomers or fibrils                                         Weakly detects annular oligomeric conformations from α-Syn and IAPP                                                      WB, IHC \[[@B189],[@B191]\]
                                 6E10       Amino acid 4-9 in Aβ sequence                                                           Detects monomers, oligomers and fibrils, but does not cross-react with α-Syn or IAPP                                     WB, IHC, IP, ELISA, EM \[[@B189],[@B192]\]
  Tau                            T22        Human Tau oligomers; conformationally specific epitope                                  Reported to have no significant cross-reaction with monomers or fibrils of Tau, or with α-Syn, IAPP, or Aβ in any form   WB, IHC, IP ELISA \[[@B193]-[@B195]\]
                                 TOMA       Human Tau oligomers; conformationally specific epitope                                  No cross-reaction with Tau monomers or fibrils, or with Aβ or α-Syn                                                      WB ,IHC, ELISA \[[@B193]\]
  α-Syn                          Syn211     Amino acid 121-125 of human α-Syn sequence                                              Does not cross-react with mouse or rat subtypes. Does not cross-react with β-Syn or β-Syn.                               WB, IHC, IP, IF \[[@B164]\]
                                 Syn-O2     Oligomers, weakly recognizes residue 127-140 of the α-Syn sequence                      Does not detect monomers, but detects some fibril                                                                        WB, IP, IHC \[[@B196],[@B197]\]
  Huntingtin (Htt)               3B5H10     PolyQ in a compact β-strand configuration                                               Recognizes diseased-associated Htt from human and murine origin; no detectable binding to normal Htt                     WB, IHC, IP, ELISA \[[@B8],[@B198]-[@B200]\]
                                 MW1        PolyQ domain of Htt exon 1                                                              Recognizes diseased-associated Htt from human and murine origin; no detectable binding to normal Htt                     WB, IHC \[[@B200],[@B201]\]
  Prion protein PrPC and PrPSc   6D11       PrpC, human origin; epitope within residues 93-109                                      Also detects PrPSc. Cross-reacts with prion proteins from cervines, ovine, murine and cricetine                          WB, IHC, ELISA, IF \[[@B202],[@B203]\]
                                 G-12       Amino acid 217-232 human sequence                                                       Murine, human                                                                                                            WB, IP, IF and ELISA \[[@B204]\]
                                 PRC5       Needs Ala in position 136                                                               PrP from murine, cervines, bovine, ovine, equine, cricetine, mustelines, sciurine, primates                              WB \[[@B205]\]
                                 D18        PrPC, conformationally specific epitope related to Helix 1, residues 130-160            Murine, human, recognises PrPC Only                                                                                      WB \[[@B206]-[@B209]\]
                                 ICSM18     PrPC, conformationally specific epitope related to Helix 1, residues 130-160            Murine, human, recognises PrPC Only                                                                                      WB \[[@B207]-[@B209]\]
                                 6H4        PrPSC conformationally specific epitope related to Helix 1, residues 130-160            Also recognises PrPC                                                                                                     WB \[[@B207]-[@B210]\]
  ------------------------------ ---------- --------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------

###### Identification of prion protein glycosylation states

  ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ----------------------- ------------------------------------------------------------------------------------------------------------------
  Prion Protein Glycosylation state                       Detection method                                                                                             Sample type             References and notes
  Preferential detection of aglycosyl and mono-glycosyl   Antibody PRC7; conformationally specific epitope. Residues at position 154, 166, 185 and 197 are involved.   Extract, WB             The epitope is glycosylation-dependent and residues 154 and 185 are involved \[[@B205]\]
  Sialylated and O-glycosidically linked glycans          Lectin proteins affinity for specific glycosylations                                                         Tissue, IHC             Antibodies for PrP (MAB1562 and AB5058) used to ensure that lectins actually detected prion proteins \[[@B126]\]
  Glycoproteome of prion protein variants                 708 proteins or protein variants assessed                                                                    Murine plasma samples   Combined MS-affinity chromatography based approach \[[@B211]\]
  ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ----------------------- ------------------------------------------------------------------------------------------------------------------

###### Identification of oligomeric states by mass spectrometry

  -------------------------- ----------------------------------------------- ---------------------------------------------------------------------- ------------------------------------- -------------
  Protein                    Oligomeric state detected                       Sample type                                                            MS detection method sub-type          Reference
  α-Syn                      Differentiates between oligomers and monomers   Prepared from isolated protein                                         Hydrogen-Deuterium Exchange, ESI-MS   \[[@B212]\]
  α-Syn                      Monomers and oligomers                          Prepared from isolated protein                                         ESI-ion mobility mass spectrometry    \[[@B213]\]
  α-Syn                      Differentiates between oligomers and monomers   Conditioned cell media, similar in complexity to Cerebrospinal Fluid   Combined MS-antibody based approach   \[[@B214]\]
  APP, Prion Protein, DJ-1   Monomers and oligomers                          Cerebrospinal Fluid                                                    Tandem MS/MS                          \[[@B215]\]
  Prion Protein              Differentiates between PrPC and PrPSc           Samples prepared from brain homogenate                                 Quantitative LC--MS/MS                \[[@B216]\]
  -------------------------- ----------------------------------------------- ---------------------------------------------------------------------- ------------------------------------- -------------

The problems inherent in the types of detection discussed here---low concentration of target protein, subtle differences between correctly and incorrectly folded and aggregated proteins, heterogeneous protein modifications and strong background signals when detecting in a complex biological environment---do not have obvious solutions. However, it seems likely that protein affinity-based techniques (antibodies, lectins) can successfully be combined with instrument-based detection methods, such as mass-spectrometry, fluorescence, and surface plasmon resonance to produce sensitive detection methods able to identify both the aggregation state and modification state of the protein in question. Moreover, there is reason to believe that early detection can give the patient time to benefit from emerging medical technologies such as antibody-based inhibition of oligomer formation \[[@B127]\].
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AD

:   Alzheimer's Disease

APP

:   Amyloid Precursor Protein

Aβ

:   Beta-Amyloid

BSE

:   Bovine Spongiform Encephalopathy

CJD

:   Creutzfeldt-Jakob Disease

CNS

:   Central Nervous System

IF

:   Immunofluorescence

IP

:   Immunoprecipitation

ELISA

:   Enzyme Linked Immunosorbent Assay

Htt

:   Huntingtin

HD

:   Huntington's Disease

IHC

:   Immunohistochemistry

LCOs

:   Luminescent Conjugated Oligothiophenes

PD

:   Parkinson's Disease

PrPC

:   Prion Protein Cellular

PrPSc

:   Prion Protein Scrapie-associated

PMD

:   Protein Misfolding Disease

*α*-Syn

:   *α*-Synuclein

WB

:   Western Blot
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